0.2158

2.44% -0.0054

After Hours: .21 -0.0058 -2.69%

Jupiter Neurosciences Inc (JUNS)

Overview News Price History Discussions Forecast

Jupiter Neurosciences Inc stock is traded at $0.2158, with a volume of 1.19M. It is down -2.44% in the last 24 hours and down -10.86% over the past month. Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Previous Close:

$0.2212

Open:

$0.2217

24h Volume:

1.19M

Relative Volume:

0.19

Market Cap:

$10.41M

Revenue:

$40,400

Net Income/Loss:

$-9.18M

P/E Ratio:

-0.804

EPS:

-0.2684

Net Cash Flow:

$-5.78M

1W Performance:

+0.75%

1M Performance:

-10.86%

6M Performance:

-79.35%

1Y Performance:

-85.32%

1-Day Range:

$0.2084

$0.2261

1-Week Range:

$0.2075

$0.2299

52-Week Range:

$0.1721

$3.33

Jupiter Neurosciences Inc Stock (JUNS) Company Profile

Name

Jupiter Neurosciences Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

(561) 406-6154

Address

1001 NORTH US HWY 1, JUPITER

Employee

Twitter

Next Earnings Date

2026-08-17

Latest SEC Filings

JUNS's Discussions on Twitter

Compare JUNS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JUNS Jupiter Neurosciences Inc	0.2158	10.67M	40,400	-9.18M	-5.78M	-0.2684
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Jupiter Neurosciences Inc Stock (JUNS) Latest News

09:35 AM

Jupiter Neurosciences appoints Tomas Philipson to board - Investing.com

09:35 AM

08:58 AM

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson - GlobeNewswire

08:58 AM

Jul 04, 2026

Price to book forward of Jupiter Neurosciences, Inc. – NASDAQ:JUNS - TradingView

Jul 04, 2026

JUNS Q4 2025 Earnings: EPS Beat Offers Optimism Despite No RevenueRevenue Warning Signal - dars.gov.et

Jul 04, 2026

Jun 30, 2026

Jupiter Neurosciences, Inc. Files Form 8-K: Nasdaq Listed Emerging Growth Company Overview - Minichart

Jun 30, 2026

Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill

Jun 29, 2026

A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits

Jun 29, 2026

Top Premarket Decliners - Moomoo

Jun 29, 2026

Get insights into the top gainers and losers of Monday's pre-market session. - ChartMill

Jun 29, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jun 29, 2026

Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarke - Benzinga

Jun 29, 2026

Jun 27, 2026

Form S-1 Jupiter Neurosciences Inc For: 26 June By Investing.com - Investing.com Nigeria

Jun 27, 2026

Jun 26, 2026

Jupiter Neurosciences files for resale of up to 16M shares by Yorkville - scanx.trade

Jun 26, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Jun 26, 2026

JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN

Jun 26, 2026

Friday's after hours session: top gainers and losers - ChartMill

Jun 26, 2026

Jupiter NeurosciencesFiles For Resale Of Up To 16 Million Shares By Selling StockholderSEC Filing - TradingView

Jun 26, 2026

Yorkville to resell 16M Jupiter Neurosciences (NASDAQ: JUNS) shares under SEPA - Stock Titan

Jun 26, 2026

Jun 25, 2026

Jupiter Neurosciences, Inc. Actuals & Estimates (NASDAQ:JUNS) - TradingView

Jun 25, 2026

Jun 23, 2026

JUNSJupiter Neurosciences Inc Earnings - Finviz

Jun 23, 2026

Jun 22, 2026

Form DEF 14A Jupiter Neurosciences Inc For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

[ARS] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan

Jun 22, 2026

Form 8K Jupiter Neurosciences Inc For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

Jupiter Neurosciences director Allison W. Brady resigns from board By Investing.com - Investing.com Nigeria

Jun 22, 2026

Jupiter Neurosciences Announces Board Member Resignation and Vacancy - TipRanks

Jun 22, 2026

Jupiter Neurosciences director Allison W. Brady resigns from board - Investing.com

Jun 22, 2026

Jupiter Neurosciences (JUNS) seeks reverse split and larger equity plan - Stock Titan

Jun 22, 2026

Jupiter Neurosciences, Inc. Announces CEO Change in Nasdaq Filing – 8-K SEC Report June 2026 - Minichart

Jun 22, 2026

Allison Brady resigns from Jupiter Neurosciences Board (NASDAQ: JUNS) - Stock Titan

Jun 22, 2026

Allison W. Brady resigns from Jupiter Neurosciences board and committees - TradingView

Jun 22, 2026

Director Allison W. Brady resigns from Jupiter Neurosciences (NASDAQ: JUNS) board - Stock Titan

Jun 22, 2026

Jun 17, 2026